학술논문

JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo
Document Type
Article
Source
In Blood 28 August 2014 124(9):1492-1501
Subject
Language
ISSN
0006-4971